Kyverna Therapeutics

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.

101-250 employees

Biotechnology

Public Company

Website LinkedIn Email Share Tweet

Biotechnology Therapeutics Life Science

Hybrid Work Model

This company offers a hybrid work model combining remote and office work.

Open Positions7

Remote ideally based SoCal, AZ, NV, UTFull-TimeBiopharmaceuticalPosted

Medical Science Liaison/Senior Medical Science Liaison

Identify, establish, and maintain high‑quality scientific relationships with key opinion leaders, investigators, and academic medical centers.
Provide fair‑balanced, accurate, and compliant scientific exchange related to disease state and Kyverna’s CAR‑T programs.
Develop and execute geography‑specific Medical Affairs and KOL engagement plans.
Collaborate with Clinical Development and Operations to support trial site identification and enrollment feasibility.
Capture and translate external medical insights to inform internal clinical and development strategy.
Represent the company at national, regional, and local medical congresses and advisory boards.

Showing 1 of 7 positions

About Kyverna Therapeutics

Kyverna Therapeutics is pioneering a new class of treatments to potentially cure serious autoimmune diseases. We combine advanced T-cell engineering and synthetic biology to target the root cause of inflammatory diseases. Our platform focuses on developing CAR T-cell therapies, including KYV-101 in Phase 2 trials for multiple autoimmune conditions. Kyverna has raised $322 million and became public in February 2024, trading on Nasdaq as KYTX.

How We Work

We embrace a patient-centered approach, guided by core values like 'Stay True to Why' and 'Collaborate to Accelerate'. Our flexible work environment includes remote and hybrid options. We foster an open, supportive, and inclusive culture that encourages continuous learning and growth for our team of 100-250 employees.

Innovation at Kyverna

Our therapeutic platform combines cutting-edge T-cell engineering and synthetic biology. We suppress and eliminate autoreactive immune cells to treat inflammatory diseases. Our pipeline includes Mivocabtagene autoleucel (miv-cel, KYV-101), KYV-102, and KYV-201. These investigational CAR T-cell therapies aim to transform autoimmune disease treatment. We are developing solutions like Ingenui-T, a rapid manufacturing process that uses whole blood for cell therapy candidates.

Why Join Us

Pioneer novel CAR T-cell therapies to cure serious autoimmune diseases.
Contribute to a public company with $322 million in funding, ensuring significant impact.
Work in a flexible, remote-first environment with a focus on collaboration and innovation.
Shape the future of medicine in a rapidly growing biotechnology field.
Receive a robust benefits package, including equity grants and performance bonuses.

Benefits & Perks

Unlimited Flexible PTO, including Holidays and Winter Shutdown
Generous company-subsidized medical, dental, and vision insurance
401(k) retirement with company match
Equity grants and performance bonuses
Parental Leave and Employee Assistance Program (EAP)
Commuter benefits, onsite gym, legal protection, and discount programs

Tech Stack

widgets

Similar Companies